Search

Displaying results 4151 - 4160 of 7540 in total
  1. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    It is developed by Cellerix and is in phase I of clinical trials. … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of

  2. Drug

    Tedisamil

    go.drugbank.com/drugs/DB06200
    Experimental

    It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.

  3. Drug

    Linaprazan glurate

    go.drugbank.com/drugs/DB21534
    Investigational

    The usage of the INN stem '-prazan' in the name indicates that Linaprazan glurate is a proton pump inhibitor, not dependent on acid activation. … to Gastroesophageal Reflux Disease (GERD)).

  4. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. … Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials.

  5. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  6. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets. … Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

  7. Drug

    XmAb 2513

    go.drugbank.com/drugs/DB06324
    Investigational

    XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types.

  8. Drug

    Butyrylthiocholine

    go.drugbank.com/drugs/DB04250
    Experimental

    A sulfur-containing analog of butyrylcholine which is hydrolyzed by butyrylcholinesterase to butyrate and thiocholine. It is used as a reagent in the determination of butyrylcholinesterase activity.

  9. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]

    Synonyms: 1-Pyrrolidinecarboxamide, 3,3-dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-, 3,3-Dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-1-pyrrolidinecarboxamide
  10. Drug

    Indecainide

    go.drugbank.com/drugs/DB00192
    Approved

    Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics